Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
At GlycoMimetics, we are committed to helping to make a difference in the lives of...
At GlycoMimetics, we are committed to helping t...
OpGen, Inc. is a precision medicine company harnessing the power of molecular diag...
OpGen, Inc. is a precision medicine company har...
Cerus Corporation is dedicated solely to safeguarding the worldâs blood supply a...
Cerus Corporation is dedicated solely to safegu...
Fresenius is a global healthcare group offering high-quality products and services...
Fresenius is a global healthcare group offering...
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncol...
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) ...
Virtuoso Surgical, Inc. was born out of a collaborative research effort developing...
Virtuoso Surgical, Inc. was born out of a colla...
NantKwest is an innovative clinical-stage immunotherapy company focused on harness...
NantKwest is an innovative clinical-stage immun...
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...
Gritstone Oncology is developing tumor-specific...
Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...
Merus is a clinical-stage immuno-oncology compa...
ArQule is a biopharmaceutical company engaged in the research and development of t...
ArQule is a biopharmaceutical company engaged i...
Join the National Investor Network and get the latest information with your interests in mind.